Jason S. Starr, DO, discusses DLL3 as a treatment target in extrapulmonary neuroendocrine carcinomas.
Jason Starr, DO
Advertisement
Articles by Jason Starr, DO
Jason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5